[(4-aminomethyl-piperidin-1-yl)-imino-methyl]amine dihydrochloride | 283162-65-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: [(4-aminomethyl-piperidin-1-yl)-imino-methyl]amine dihydrochloride
• 英文别名: 4-aminomethyl-piperidine-1-carboxamidine dihydrochloride；4-Aminomethyl-piperidine-1-carboxamidine hydrochloride；4-(aminomethyl)piperidine-1-carboximidamide;hydrochloride
• CAS: 283162-65-2
• 化学式: C₇H₁₆N₄*2ClH
• 分子量: 229.153
• InChiKey: FIIGHXBSUOEXGM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.03
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  79.1
• 氢给体数：
  4
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-((3-(4-(difluoromethoxy)phenyl)imidazo[1,2-a]pyrazin-8-yl)amino)-2-methylbenzoic acid 、 [(4-aminomethyl-piperidin-1-yl)-imino-methyl]amine dihydrochloride 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 N-((1-carbamimidoylpiperidin-4-yl)methyl)-4-((3-(4-(difluoromethoxy)phenyl)imidazo[1,2-a]pyrazin-8-yl)amino)-2-methylbenzamide
  参考文献：
  名称：

  [EN] NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS
  [FR] NOUVEAUX DÉRIVÉS D'IMIDAZOPYRAZINE EN TANT QU'ANTIBACTÉRIENS

  摘要：

  这项发明提供了具有通式（I）的新型咪唑吡嗪衍生物，其中R1至R11如本文所述，并其药学上可接受的盐。还提供了包括这些化合物的药物组合物、制造这些化合物的方法以及将这些化合物用作药物的方法，特别是将这些化合物用作抗生素治疗或预防细菌感染及相关疾病的方法。

  公开号：

  WO2020126953A1

文献信息

• Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1022268A1

  公开（公告）日：2000-07-26

  The present invention relates to new compounds for the inhibition of blood clotting proteins, and more particularly, to arylalkanoyl derivatives of the formula I, wherein R(1), R(2), R(3), R(4), R(5), R(6a) and R(6b) have the meanings indicated in the claims. The compounds of formula I are inhibitors of the blood clotting enzyme factor Xa. The invention also relates to processes for the preparation of the compounds of formula I, to methods of inhibiting factor Xa activity and of inhibiting blood clotting, to the use of the compounds of formula I in the treatment and prophylaxis of diseases, which can be treated or prevented by the inhibition of factor Xa activity such as thromboembolic diseases, to and the use of the compounds of formula I in the preparation of medicaments to be applied in such diseases. The invention further relates to compositions containing a compound of formula I in admixture or otherwise in association with an inert carrier, in particular pharmaceutical compositions containing a compound of formula I together with pharmaceutically acceptable carrier substances and auxiliary substances.

  本发明涉及用于抑制血液凝固蛋白的新化合物，更具体地，是指式I的芳烷酰衍生物， 其中R(1)、R(2)、R(3)、R(4)、R(5)、R(6a)和R(6b)的含义如权利要求中所示。式I的化合物是血液凝固酶因子Xa的抑制剂。本发明还涉及制备式I化合物的方法，抑制因子Xa活性和血液凝固的方法，使用式I化合物治疗和预防可以通过抑制因子Xa活性来治疗或预防的疾病，如血栓栓塞性疾病，以及使用式I化合物制备用于治疗上述疾病的药物。本发明还涉及包含式I化合物的组合物，与惰性载体混合或以其他方式相关联，尤其是包含式I化合物的药物组合物，以及药用可接受的载体物质和辅助物质。
• Guanidine and amidine derivatives as factor Xa inhibitors
  申请人：——

  公开号：US20020173656A1

  公开（公告）日：2002-11-21

  The present invention relates to compounds of the formula I, 1 in which R 0 ; Q; X; Q′, D, R 10 and V have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及公式I的化合物，其中R0；Q；X；Q′；D；R10和V具有所述权利要求中指示的含义。公式I的化合物是有价值的药理活性化合物。它们表现出强烈的抗血栓作用，适用于治疗和预防心血管疾病，如血栓栓塞性疾病或再狭窄。它们是血凝酶因子Xa（FXa）和/或因子VIIa（FVIIa）的可逆抑制剂，通常可应用于存在因子Xa和/或因子VIIa不良活性的情况，或者用于治疗或预防需要抑制因子Xa和/或因子VIIa的疾病。本发明还涉及公式I化合物的制备方法，它们的使用，特别是作为药物的活性成分，以及包含它们的制药制剂。
• ARYLALKANOYL DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1150946B1

  公开（公告）日：2005-03-30
• GUANIDINE AND AMIDINE DERIVATIVES AS FACTOR XA INHIBITORS
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1345900A1

  公开（公告）日：2003-09-24
• US6759420B1
  申请人：——

  公开号：US6759420B1

  公开（公告）日：2004-07-06